Stock Analiz

Moleculin Biotech, Inc. MBRX

Biotechnology: Pharmaceutical Preparations · IPO 2016 · data as of November 13, 2026

$7.87Market cap $8M
Open the interactive analysis →

Moleculin Biotech, Inc. (MBRX) is a healthcare company listed in the US with a market value of about $8M.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -107%.

About Moleculin Biotech

Moleculin Biotech is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2016. It was profitable in 0 of the last 10 years in our data. Its share count fell by 38% over three years (buybacks).

Score: 0.6 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Share count down over 3 years (buybacks)

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B0.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-275.1%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-106.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$0$0$0$0$0$0$0$0$0$0
Net income-$34M-$26M-$30M-$29M-$16M-$17M-$13M-$12M-$10M-$4M
Free cash flow-$23M-$24M-$24M-$28M-$19M-$18M-$17M-$13M-$7M-$4M
EPS (diluted)$-28.42$-189.14$-15.07$-15.22$-0.59$-1.76$-1.95$-2.76$-3.18$-2.40
Net margin——————————
ROIC-163.4%-228.0%-74.3%-46.0%-22.9%-109.5%-108.0%-83.2%-39.9%-20.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 3 analysts is $240.00, 2950% above the current price; targets range from $40.00 to $620.00; the consensus rating is “none”; expected EPS is $-65.33 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Moleculin Biotech pay a dividend?

Not currently.

Is Moleculin Biotech a good stock to buy?

We do not give buy or sell advice. Moleculin Biotech scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.